[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"skill:01M7ED0ZPQNJM10WZ2F8ZVBKTP":3,"skill-same:01M7ED0ZPQNJM10WZ2F8ZVBKTP":62},{"skillNo":4,"name":5,"nameZh":6,"description":7,"descriptionZh":6,"repositoryFullName":8,"ownerLogin":9,"ownerAvatarUrl":10,"ownerAccountNo":11,"ownerDisplayName":12,"repositoryNo":13,"starsCount":14,"licenseSpdxId":15,"licenseFileUrl":6,"sourceHtmlUrl":16,"categories":17,"keywords":18,"publishedAt":19,"linkOnly":20,"markdownContent":21,"markdownBody":22,"frontMatter":23,"refName":30,"commitSha":31,"skillDirectory":32,"forksCount":14,"repositoryHtmlUrl":33,"repositoryHomepageUrl":33,"ownerHtmlUrl":34,"ownerBlogUrl":6,"ownerDescription":6,"updatedAt":35,"install":36,"resources":49},"01M7ED0ZPQNJM10WZ2F8ZVBKTP","bio-epidemiological-genomics-amr-surveillance",null,"Detects acquired antimicrobial-resistance determinants and chromosomal point-mutation resistance in bacterial assemblies using AMRFinderPlus, ResFinder 4.0 (acquired + PointFinder), CARD-RGI, abritAMR, staramr, and species-specific callers (TB-Profiler, Mykrobe). Harmonises cross-tool output via hAMRonization, contextualises determinants with mobile-genetic-element annotation (MOB-suite, PlasmidFinder, MobileElementFinder, ICEberg), predicts phenotype against EUCAST or CLSI breakpoints, and translates calls into WHO GLASS reporting categories. Use when screening clinical or surveillance isolates for AMR, distinguishing acquired vs intrinsic vs point-mutation resistance, calling rpoB \u002F katG \u002F pncA \u002F gyrA \u002F mgrB mutations, reconciling AMRFinderPlus vs RGI vs ResFinder disagreement, contextualising carbapenemases or mcr alleles on plasmids, predicting susceptibility from genotype against the WHO Mtb 2nd-edition catalogue, or building a hAMRonized multi-lab AMR surveillance pipeline.","Mr-Nobody-Anonymous\u002FAll-skills","Mr-Nobody-Anonymous","https:\u002F\u002Favatars.githubusercontent.com\u002Fu\u002F184253119?v=4","01M7AEXFJHKTYQW5R0ZCQQTWFV","anonymous","01M7C00M3GQR4QKP9GZA42GFAK",0,"MIT","https:\u002F\u002Fgithub.com\u002FMr-Nobody-Anonymous\u002FAll-skills\u002Fblob\u002Fmain\u002Fawesome_skills\u002Fbiology\u002Fbio-epidemiological-genomics-amr-surveillance\u002FSKILL.md",[],[],"2026-11-15 14:19:17",false,"---\nname: bio-epidemiological-genomics-amr-surveillance\ndescription: Detects acquired antimicrobial-resistance determinants and chromosomal point-mutation resistance in bacterial assemblies using AMRFinderPlus, ResFinder 4.0 (acquired + PointFinder), CARD-RGI, abritAMR, staramr, and species-specific callers (TB-Profiler, Mykrobe). Harmonises cross-tool output via hAMRonization, contextualises determinants with mobile-genetic-element annotation (MOB-suite, PlasmidFinder, MobileElementFinder, ICEberg), predicts phenotype against EUCAST or CLSI breakpoints, and translates calls into WHO GLASS reporting categories. Use when screening clinical or surveillance isolates for AMR, distinguishing acquired vs intrinsic vs point-mutation resistance, calling rpoB \u002F katG \u002F pncA \u002F gyrA \u002F mgrB mutations, reconciling AMRFinderPlus vs RGI vs ResFinder disagreement, contextualising carbapenemases or mcr alleles on plasmids, predicting susceptibility from genotype against the WHO Mtb 2nd-edition catalogue, or building a hAMRonized multi-lab AMR surveillance pipeline.\ntool_type: mixed\nprimary_tool: AMRFinderPlus\nsource: \"https:\u002F\u002Fgithub.com\u002FGPTomics\u002FbioSkills\"\nsource_repository: \"GPTomics\u002FbioSkills\"\nsource_path: \"epidemiological-genomics\u002Famr-surveillance\u002FSKILL.md\"\nlicense: \"MIT\"\nimported_at: \"2026-09-20\"\n---\n\n## Version Compatibility\n\nReference examples tested with: ncbi-amrfinderplus 4.0+, resfinder 4.5+, rgi 6.0+ (CARD 3.3+), abritamr 1.0.14+, staramr 0.10+, hamronization 1.1+, tb-profiler 6.2+, mykrobe 0.13+, mob_suite 3.1+, plasmidfinder 2.1+, MobileElementFinder 1.0+, pandas 2.2+, BioPython 1.84+.\n\nBefore using code patterns, verify installed versions match. If versions differ:\n- Python: `pip show \u003Cpackage>` then `help(module.function)` to check signatures\n- CLI: `\u003Ctool> --version` then `\u003Ctool> --help` to confirm flags\n- AMRFinderPlus: `amrfinder --list_organisms` for the current `--organism` catalogue\n- WHO Mtb catalogue: `tb-profiler list_db` and verify the bundled WHO edition\n- AMR database freshness: `amrfinder -u` (NCBI ReferenceGeneCatalog) and `tb-profiler update_tbdb`\n\nIf a flag or column name does not match (`--species` vs `--organism`, `barcode_build` vs `barcode-build`), introspect the installed package rather than retrying. AMRFinderPlus, RGI, and ResFinder all renamed columns between major releases.\n\n# AMR Surveillance\n\n**\"What antibiotic-resistance determinants are in this assembly, and what susceptibility do they imply?\"** -> Combine acquired-gene detection, chromosomal point-mutation calling, mobile-element context, and curated phenotype mapping into a single per-isolate report fit for surveillance or clinical handover. Tool choice is determined by species (Mtb needs TB-Profiler, not AMRFinderPlus), reporting standard (WHO GLASS vs CARD vs in-house), and whether mobility matters (carbapenemase outbreak: yes; routine ESBL screen: less so).\n\n- CLI: `amrfinder -n assembly.fa --organism Klebsiella_pneumoniae --plus` -- acquired + intrinsic-aware point mutations\n- CLI: `tb-profiler profile -1 r1.fq.gz -2 r2.fq.gz -p sample` -- TB drug-resistance against WHO 2nd-edition catalogue\n- CLI: `hamronize amrfinderplus --analysis_software_version 4.0.3 --reference_database_version 2025-02-01.1 in.tsv > out.tsv` -- normalise output across tools\n- Python: `pandas` to join AMRFinderPlus + RGI + ResFinder + MOB-suite per-isolate for a single decision table\n\n## The Single Most Important Modern Insight -- Acquired AMR detection is not species-agnostic\n\nA pan-species AMRFinderPlus run misses chromosomal point-mutation resistance because the point-mutation panels are species-specific and activated only when `--organism` is set. Running `amrfinder -n mtb.fa` without `--organism` returns \"no AMR detected\" on an XDR-TB genome because AMRFinderPlus has no Mtb organism mode -- the user must switch tools (TB-Profiler or Mykrobe + WHO 2nd-edition catalogue). Similarly, *Salmonella* gyrA T83I, *Klebsiella* mgrB inactivation, and *E. coli* QRDR mutations are silent without `--organism Salmonella` \u002F `Klebsiella_pneumoniae` \u002F `Escherichia`. For any cross-tool surveillance pipeline, AMRFinderPlus with `--organism` MUST be paired with a species-specific second tool (TB-Profiler for Mtb; ResFinder 4.0 with `-s 'species'` for PointFinder coverage; hAMRonization to merge). Andersson et al. *Nat Rev Microbiol* 17:479 (2019) further notes that heteroresistance at 0.1-1% allele frequency is widespread and invisible to default variant callers, compounding the failure mode for any single-tool workflow.\n\n## Algorithmic Taxonomy\n\n| Tool | Mechanism | Inputs | Output | Strength | Fails when |\n|------|-----------|--------|--------|----------|------------|\n| AMRFinderPlus (Feldgarden 2021 *Sci Rep* 11:12728) | Curated HMM + BLAST against NCBI ReferenceGeneCatalog; per-gene cutoffs | assembly or protein | gene + class + element-type | Gene-family-aware (catches divergent variants); built-in species point-mutation panels | No Mtb mode; reports intrinsic genes unless `--organism` set |\n| ResFinder 4.0 (Bortolaia 2020 *J Antimicrob Chemother* 75:3491) | BLAST against ResFinder DB (acquired) + PointFinder DB (chromosomal mutations) per species | assembly or reads | gene + predicted phenotype (S\u002FI\u002FR) | Phenotype prediction tied to CLSI\u002FEUCAST | Requires explicit `-s 'species'` for PointFinder; default 90\u002F60 cutoffs hide divergent variants |\n| CARD-RGI (Alcock 2023 *NAR* 51:D690) | BLAST + HMM against CARD; tiers Perfect \u002F Strict \u002F Loose | assembly or protein | ARO ontology term, model-type (homolog \u002F variant \u002F overexpression \u002F knockout \u002F rRNA) | Mechanism-resolved (operons modelled); ARO ontology is curated | Loose tier produces many false positives; default Strict+Perfect misses real variants in non-model organisms |\n| abritAMR (Sherry 2023 *Nat Commun* 14:60) | AMRFinderPlus wrapper + drug-class classifier; ISO-certified for clinical use | assembly | gene + drug class | First ISO-certified AMR pipeline; accredited reporting categories | Limited to AMRFinderPlus's underlying gene panel |\n| staramr | ResFinder + PointFinder + PlasmidFinder + MLST in one pipeline | assembly | combined report | One-shot Salmonella \u002F E. coli \u002F Campylobacter surveillance | Default organism handling can hide point mutations; verify each component version |\n| TB-Profiler (Phelan 2019 *Genome Med* 11:41) | Maps reads or assembly against H37Rv + WHO catalogue + Coll\u002FNapier lineage barcode | reads or assembly | per-drug R\u002FR-interim\u002FUncertain\u002FS + lineage | WHO 2nd-edition catalogue integration; lineage call; heteroresistance from allele frequency | Hardcoded to MTBC; older bundled DB may predate current WHO edition |\n| Mykrobe (Hunt 2019 *Wellcome Open Res* 4:191) | k-mer presence\u002Fabsence against curated panel | reads | species + AMR per drug | k-mer-fast; cross-checks TB-Profiler; supports Mtb, S. aureus, Salmonella, gonorrhoea | Panel may lag WHO catalogue; check `--panel` |\n| hAMRonization (PHA4GE) | Format converter to PHA4GE schema | per-tool TSV | unified TSV\u002FJSON | Cross-tool comparison; surveillance harmonisation | Mandatory metadata fields differ per tool subparser |\n\n## Decision Tree by Scenario\n\n| Scenario | Recommended | Why wrong choices fail |\n|----------|-------------|------------------------|\n| Routine screen of an *E. coli* \u002F *Klebsiella* \u002F *Salmonella* assembly for acquired AMR + point mutations | AMRFinderPlus with `--organism Escherichia` \u002F `Klebsiella_pneumoniae` \u002F `Salmonella` + `--plus` | Without `--organism`: no PointFinder panel, fluoroquinolone QRDR mutations missed; intrinsic-gene noise in Klebsiella |\n| *M. tuberculosis* drug-resistance prediction | TB-Profiler interpreted via WHO 2nd-edition catalogue, Mykrobe as cross-check on R\u002FXDR isolates | AMRFinderPlus has no Mtb organism mode; ResFinder PointFinder lacks the full WHO catalogue; tool defaults silently call Group 3 mutations as \"susceptible\" |\n| Predict S\u002FI\u002FR phenotype, not gene presence | ResFinder 4.0 OR abritAMR; document EUCAST or CLSI breakpoint year | AMRFinderPlus reports presence only; mapping presence -> phenotype needs curated rules |\n| Carbapenemase outbreak: is the gene mobile? | AMRFinderPlus -> MOB-suite (`mob_recon` + `mob_typer`) -> cross-reference; long-read or hybrid assembly recommended | PlasmidFinder alone gives replicon type but not gene-plasmid linkage; short-read draft assemblies fragment plasmid contigs and lose context |\n| Cross-laboratory surveillance reporting | Pass per-tool output through hAMRonization to PHA4GE schema; populate `analysis_software_version` and `reference_database_version` | Raw cross-tool comparison is meaningless (CARD ARO vs ResFinder name vs NCBI ReferenceGeneCatalog) |\n| Novel-variant surveillance (emergence) | AMRFinderPlus (HMM, gene-family-aware) OR CARD-RGI with Loose-tier manual review | abricate's 80\u002F80 defaults reject divergent family members; pure-BLAST defaults silently miss novel mcr \u002F OXA sub-variants |\n| Quantitative AMR from metagenomic reads | AMRPlusPlus \u002F DeepARG \u002F ARGs-OAP normalised to 16S; report \"ARG abundance\" NOT \"resistance\" | Assembly-based tools fail on short reads; reporting environmental ARG counts as \"resistance\" inherits the environmental-resistome critique that homolog presence is not phenotypic resistance |\n| Colistin resistance in *Klebsiella* \u002F *Enterobacter* \u002F *Salmonella* | mcr-1 to mcr-10 acquired (AMRFinderPlus; mcr-1 originally Liu 2016 *Lancet Infect Dis* 16:161) + mgrB \u002F pmrAB \u002F phoPQ point mutations (`--organism Klebsiella_pneumoniae`) + phenotypic confirmation for mcr-9\u002F10 | mcr-9 \u002F mcr-10 frequently report without elevated MIC; treating mcr presence as \"colistin-R\" triggers infection control unnecessarily |\n| WHO GLASS submission | hAMRonization -> drug-class mapping -> EUCAST\u002FCLSI breakpoint interpretation; record breakpoint year | Gene-level reporting without class mapping cannot populate GLASS categories |\n\nMethodology evolves rapidly; before a high-stakes outbreak report, web-search \"AMRFinderPlus organism modes 2026\" and confirm the WHO Mtb catalogue edition currently bundled in TB-Profiler.\n\n## AMRFinderPlus With Species Mode\n\n**Goal:** Produce a per-isolate AMR report including acquired genes, species-specific chromosomal point mutations, stress\u002Fvirulence elements, and per-hit method and coverage metadata for downstream harmonisation.\n\n**Approach:** Run `amrfinder` with `-n` for nucleotide assembly, `--organism` to activate the species-specific point-mutation panel, `--plus` to include stress \u002F virulence \u002F heat \u002F metal, and `--report_all` when truncated-gene visibility matters. Pin the database via `amrfinder -u` -> verify `--db` matches a recorded date.\n\n```bash\nDB=$(amrfinder -V | grep -i database | awk '{print $NF}')\n\namrfinder \\\n    -n assembly.fa \\\n    --organism Klebsiella_pneumoniae \\\n    --plus \\\n    --threads 8 \\\n    -o sample.amrfinder.tsv\n\necho \"DB version: ${DB}\" >> sample.amrfinder.tsv\n```\n\nColumn semantics worth inspecting: `Element type` (AMR \u002F POINT \u002F VIRULENCE \u002F STRESS \u002F etc.), `Method` (EXACTX \u002F PARTIAL_CONTIG_END \u002F HMM \u002F etc. -- partial-contig hits flag assembly fragmentation), `% Coverage of reference sequence`, `% Identity to reference sequence`, `Class` \u002F `Subclass` (drug-class summary). `Method = PARTIAL_CONTIG_END` is the smoking gun for plasmid-context fragmentation -- consider long-read confirmation.\n\n## TB-Specific Workflow\n\n**Goal:** Generate a WHO-catalogue-aligned drug-resistance report for *M. tuberculosis* covering all 13 first-line + second-line + new\u002Frepurposed drugs, with lineage assignment via the Coll\u002FNapier MTBC barcode (90-SNP version) and explicit handling of Group 3 (Uncertain) mutations.\n\n**Approach:** TB-Profiler primary (it bundles the WHO catalogue and reports the Walker 2022 \u002F 2023 association grouping); Mykrobe as an orthogonal cross-check on any R \u002F XDR call that will drive treatment. NEVER collapse Group 3 mutations to \"susceptible\" -- the WHO catalogue's tiered scoring is load-bearing for clinical handover.\n\n```bash\ntb-profiler update_tbdb\n\ntb-profiler profile \\\n    -1 reads_R1.fq.gz \\\n    -2 reads_R2.fq.gz \\\n    -p sample \\\n    --txt --csv --pdf \\\n    --dir tbprofiler_out\n\nmykrobe predict \\\n    --sample sample \\\n    --species tb \\\n    --output sample.mykrobe.json \\\n    --format json \\\n    reads_R1.fq.gz reads_R2.fq.gz\n```\n\nAllix-Béguec et al. (CRyPTIC) *NEJM* 379:1403 (2018) established >99% negative predictive value for first-line drugs and is the basis for WGS-only DST policies; the same study showed sensitivity remains lower for bedaquiline, delamanid, linezolid, and clofazimine, so phenotypic DST is still required for second-line and new\u002Frepurposed agents in MDR\u002FXDR-TB workups. The WHO 2023 catalogue (Walker et al. *Lancet Microbe* 3:e265, 2022 for the 2021 edition methodology; 2023 second edition data) grades each mutation **Group 1** \u002F **Group 2** (Associated -- interim) \u002F **Group 3** (Uncertain) \u002F **Group 4** (Not Associated -- interim) \u002F **Group 5** (Not Associated). Reporting Group 3 as \"S\" actively misleads clinicians.\n\n## hAMRonization for Cross-Tool Reporting\n\n**Goal:** Convert per-tool AMR output (AMRFinderPlus, ResFinder, RGI, abricate, staramr, ARIBA, TB-Profiler, Mykrobe) to the PHA4GE schema so a multi-laboratory or multi-tool surveillance dataset is comparable.\n\n**Approach:** Invoke `hamronize \u003Ctool>` per input with mandatory provenance metadata (`--analysis_software_version`, `--reference_database_version`, `--input_file_name`), then `hamronize summarize` to merge.\n\n```bash\nhamronize amrfinderplus \\\n    --analysis_software_version 4.0.3 \\\n    --reference_database_version 2025-02-01.1 \\\n    --input_file_name sample.amrfinder.tsv \\\n    sample.amrfinder.tsv > sample.hamr.tsv\n\nhamronize resfinder \\\n    --analysis_software_version 4.5.0 \\\n    --reference_database_version 2024-12-15 \\\n    --input_file_name sample.resfinder.json \\\n    sample.resfinder.json > sample.resfinder.hamr.tsv\n\nhamronize summarize -t tsv -o cohort.hamr.tsv per_sample_hamr\u002F*.tsv\n```\n\nDefault reporting ontology for public-health output is NCBI ReferenceGeneCatalog. Two consequences: (1) CARD ARO terms need translation; (2) any custom gene additions need a corresponding NCBI accession before they appear in the harmonised stream.\n\n## Mobile-Genetic-Element Context\n\n**Goal:** Determine whether a clinically actionable AMR gene (carbapenemase, mcr, ESBL) sits on a chromosome, a plasmid (and which incompatibility group \u002F cluster), an integrative-conjugative element, or a transposon -- because \"gene present\" tells the infection-control team nothing about transmissibility.\n\n**Approach:** Reconstruct plasmids from the assembly with MOB-suite `mob_recon`; type each plasmid with `mob_typer`; cross-reference AMR-gene coordinates against the plasmid contig list; annotate IS elements \u002F integrons with MobileElementFinder. For surveillance-grade plasmid resolution, prefer long-read (R10.4.1 Q20+) or hybrid assemblies -- short-read draft assemblies routinely fragment plasmid contigs.\n\n```bash\nmob_recon \\\n    --infile assembly.fa \\\n    --outdir mob_out\u002F \\\n    --num_threads 4\n\nmob_typer \\\n    --infile mob_out\u002Fplasmid_AA001.fasta \\\n    --out_file mob_out\u002Fplasmid_AA001.typed.tsv\n\nmefinder find \\\n    --contig assembly.fa \\\n    --out mef_out\u002Fsample \\\n    --threads 4\n```\n\nDocument MOB-suite version explicitly: v2 and v3 cluster codes are non-interoperable, and v3.1+ adds MGE reporting. Across longitudinal surveillance crossing the v2 -> v3 boundary, the same plasmid receives different cluster IDs and appears spuriously \"novel\".\n\n## Per-Method Failure Modes\n\n### AMRFinderPlus run pan-species on a *Mycobacterium tuberculosis* assembly\n\n**Trigger:** `amrfinder -n mtb.fa` without `--organism`; AMRFinderPlus has no Mtb organism mode in any v4.x release.\n\n**Mechanism:** The species-specific point-mutation panels are activated only when a recognised `--organism` is passed. Mtb resistance is overwhelmingly chromosomal point mutation (rpoB \u002F katG \u002F inhA \u002F pncA \u002F embB \u002F gyrA \u002F rrs). With no panel active, none of these are called.\n\n**Symptom:** Empty AMR table on a phenotypically MDR\u002FXDR isolate; lineage barcode not reported (AMRFinderPlus does not call MTBC lineage).\n\n**Fix:** Switch tools. Use TB-Profiler (preferred -- bundles WHO catalogue + Coll\u002FNapier barcode) or Mykrobe; the AMRFinderPlus catalogue does not cover MTBC.\n\n### OXA-48-like family collapsed to a single bucket\n\n**Trigger:** Default per-isolate summarisers report the gene family (`bla_OXA-48-like`) rather than the allele (`bla_OXA-244`).\n\n**Mechanism:** OXA-48 (potent carbapenemase), OXA-181 (Thr213Ala -- similar activity, different plasmid), OXA-232 (Arg214Ser -- reduced carbapenemase activity), and OXA-244 (Arg214Gly -- weakest, often phenotypically susceptible to ertapenem) share >95% identity. Pipelines that report family-level summary erase the clinically actionable variant identity.\n\n**Symptom:** Surveillance report says \"OXA-48-like detected\", phenotype is borderline ertapenem-susceptible \u002F meropenem-susceptible, clinical team is confused about whether ceftazidime-avibactam is needed.\n\n**Fix:** Report the allele explicitly; never collapse to family. AMRFinderPlus reports the allele in `Gene symbol` -- preserve it through hAMRonization rather than summarising.\n\n### IS-element-mediated derepression invisible to gene-presence pipelines\n\n**Trigger:** Phenotypic high-level AmpC hyperproduction in *Enterobacter cloacae* complex \u002F *Citrobacter freundii*; or KPC over-expression on Tn4401b (100-bp promoter deletion).\n\n**Mechanism:** Resistance is mediated by IS*Ecp1* \u002F IS*26* \u002F IS*10* insertion upstream of the ampC promoter producing a strong hybrid promoter, or by Tn4401 variant. Gene presence is unchanged. Short-read assemblies fragment IS elements and collapse repeats; promoter context is lost. AMRFinderPlus \u002F RGI \u002F ResFinder report the gene; the regulatory configuration is not annotated.\n\n**Symptom:** AMR pipeline output identical for wild-type ampC carrier and the hyperproducer; clinical phenotype is divergent.\n\n**Fix:** Long-read (Nanopore R10.4.1 Q20+ or PacBio HiFi) or hybrid assembly with explicit promoter-context inspection. For Tn4401 variant typing, manual blast of the transposon region. Tools that automate this are emerging but not yet a default in surveillance pipelines.\n\n### Heteroresistance below default variant-caller thresholds\n\n**Trigger:** Routine Illumina WGS-AMR pipeline on a clinical isolate; resistance variant appears at 1-5% allele frequency.\n\n**Mechanism:** Heteroresistance -- clonal subpopulations carrying resistance at 0.1-1% (Andersson, Nicoloff, Hjort *Nat Rev Microbiol* 17:479, 2019) -- is widespread and clinically meaningful (treatment failure under antibiotic pressure). Default variant callers (`bcftools`, `lofreq` default `-q 20`, GATK HaplotypeCaller) require minor-allele frequency of typically 10-20% to call. Assembly-based pipelines (AMRFinderPlus on assembly) collapse minor variants entirely.\n\n**Symptom:** Surveillance pipeline calls \"S\" but clinical failure under therapy; subsequent sampling reveals high-level resistance.\n\n**Fix:** For clinically critical drugs, supplement assembly-based AMR with deep-read variant calling at lower MAF thresholds (`lofreq` with `-q 13 -a 0.01`), or use targeted deep-amplicon sequencing. TB-Profiler reports allele frequency for resistance calls -- inspect for heteroresistance routinely.\n\n### WHO Mtb Group 3 mutations silently called \"susceptible\"\n\n**Trigger:** TB-Profiler \u002F Mykrobe run on an Mtb isolate carrying a mutation graded Group 3 (Uncertain) in the WHO catalogue.\n\n**Mechanism:** Tools translate Group 3 calls to \"no resistance prediction\" in their summary; downstream summarisers and clinical handover forms collapse \"no prediction\" to \"S\". The Walker 2022 *Lancet Microbe* catalogue methodology explicitly separates Group 3 (Uncertain) from Group 4\u002F5 (Not Associated) for exactly this reason.\n\n**Symptom:** Patient treated as drug-susceptible; clinical failure; retrospective inspection finds Group 3 mutation that should have triggered phenotypic DST.\n\n**Fix:** Read TB-Profiler JSON output, NOT the simplified TSV. Report Group 3 mutations explicitly with \"uncertain significance -- phenotypic DST recommended\". This is widely under-communicated in surveillance pipelines.\n\n### fosA \u002F efflux-regulator hits overcalled as resistance\n\n**Trigger:** Chromosomal fosA in *Klebsiella pneumoniae* \u002F *Enterobacter* \u002F *Serratia* reported as \"fosfomycin resistant\" by ResFinder \u002F AMRFinderPlus.\n\n**Mechanism:** Chromosomal fosA confers low-level fosfomycin resistance below the EUCAST clinical breakpoint (32 mg\u002FL for urinary isolates). Treating chromosomal-fosA *E. coli* as fosfomycin-resistant withholds an oral option for uncomplicated UTI unnecessarily.\n\n**Symptom:** All *K. pneumoniae* isolates flagged \"fosfomycin-R\" regardless of plasmid context or phenotype.\n\n**Fix:** AMRFinderPlus with `--organism Klebsiella_pneumoniae` suppresses the intrinsic fosA report; verify the suppression worked. Cross-reference fosA hits with MOB-suite to determine plasmid context; only plasmid-borne or upregulated fosA should be reported as resistance.\n\n## Reconciliation: When AMR Tools Disagree\n\n| Pattern | Likely cause | Action |\n|---------|--------------|--------|\n| AMRFinderPlus calls `bla_NDM-5`; ResFinder calls `bla_NDM-1` | Allele assignment differs by reference database (NCBI ReferenceGeneCatalog vs ResFinder DB); both are within the NDM family | Report the family + flag the allele discordance; for clinical handover prefer NCBI nomenclature, for legacy comparability prefer ResFinder |\n| RGI calls `mecA` \"Strict\"; AMRFinderPlus calls \"EXACTX\" | Tier semantics differ; both real hits | Concordant resistance call -- harmonise via hAMRonization, use NCBI ReferenceGeneCatalog nomenclature |\n| ResFinder reports a gene at 88% identity; AMRFinderPlus omits | ResFinder default 90\u002F60; AMRFinderPlus HMM cutoff stricter for that family | Manual review; for novel-variant surveillance, AMRFinderPlus + Loose-tier RGI catches more |\n| TB-Profiler and Mykrobe disagree on isoniazid | Different curated panels; one may predate WHO 2nd edition | Defer to TB-Profiler interpreted against WHO catalogue; manual blast of katG \u002F inhA \u002F fabG1 |\n| mcr-9 detected; phenotypic colistin MIC susceptible | Expected -- mcr-9 frequently silent without IqrR \u002F induction | Report mcr-9 detection + susceptibility; do NOT trigger infection-control as if MCR-1 |\n| AMRFinderPlus `Method=PARTIAL_CONTIG_END` for a carbapenemase | Assembly fragmentation at the plasmid edge | Re-assemble with long reads or hybrid before reporting; the gene may be present in full |\n| RGI calls a long list of \"Loose\" hits | Non-model organism or distant lineage | Manual curation of Loose hits -- discard generic homologs, retain those near canonical AMR-active residues |\n\n## Quantitative Thresholds\n\n| Quantity | Threshold | Source \u002F rationale |\n|----------|-----------|--------------------|\n| AMRFinderPlus default %identity | per-gene curated (typically 90% global) | Feldgarden 2021 *Sci Rep* 11:12728; HMM cutoff is gene-family-aware |\n| AMRFinderPlus default %coverage | 50% (alignment coverage) | NCBI Reference; `--report_all` exposes partial hits |\n| ResFinder default %id \u002F %coverage | 90% \u002F 60% | CGE convention; tighter than abricate |\n| abricate default %id \u002F %coverage | 80% \u002F 80% | Too permissive for novel-variant surveillance |\n| WHO Mtb Group 1 (Associated with R) | High-confidence resistance call | Walker 2022 *Lancet Microbe* 3:e265 |\n| WHO Mtb Group 3 (Uncertain) | NOT \"susceptible\" -- phenotypic DST recommended | Walker 2022 *Lancet Microbe* 3:e265; 2023 2nd edition data |\n| Heteroresistance MAF | 0.1-1% (deep amplicon detection) | Andersson 2019 *Nat Rev Microbiol* 17:479 |\n| EUCAST fosfomycin urinary breakpoint | 32 mg\u002FL | EUCAST clinical breakpoint tables (year-specific) |\n| Variant MAF for routine WGS-AMR calling | 10% (`lofreq` default), 20% (GATK default) | Tool defaults; document per-pipeline |\n\n## Common Errors\n\n| Error \u002F symptom | Cause | Solution |\n|-----------------|-------|----------|\n| AMRFinderPlus empty on TB assembly | No Mtb `--organism` mode | Switch to TB-Profiler \u002F Mykrobe |\n| AMRFinderPlus calls intrinsic fosA on Klebsiella | `--organism` not set; intrinsic suppression off | Always pass `--organism` for the species |\n| `--species` flag rejected | AMRFinderPlus uses `--organism`, not `--species` | Use `--organism Klebsiella_pneumoniae` |\n| Different gene names for same determinant across tools | CARD ARO vs ResFinder vs NCBI ReferenceGeneCatalog | Pass through `hamronize` |\n| `Method=PARTIAL_CONTIG_END` on a clinically critical gene | Assembly fragmentation | Re-assemble with long reads \u002F hybrid |\n| `hamronize` rejects input as missing metadata | `--analysis_software_version` not supplied | Populate all mandatory PHA4GE fields per tool subparser |\n| MOB-suite cluster codes don't match published outbreak paper | v2 vs v3 incompatibility | Re-run with matched MOB-suite version; document |\n| Point-mutation panel coverage list flips between AMRFinderPlus minor releases | DB schema change | `amrfinder --list_organisms` and record the version |\n| TB-Profiler bundled DB predates WHO 2nd edition | DB not updated | `tb-profiler update_tbdb` and verify catalogue edition |\n\n## Anticipated Reviewer Pushback\n\n| Pushback | Response |\n|----------|----------|\n| \"Why AMRFinderPlus, not RGI?\" | AMRFinderPlus uses gene-family HMMs and NCBI-curated cutoffs that catch divergent novel variants without producing the Loose-tier noise of RGI; both are valid and `hamronize` lets the reviewer compare |\n| \"How were Group 3 WHO Mtb mutations handled?\" | Reported as \"Uncertain significance -- phenotypic DST recommended\"; not collapsed to S |\n| \"What about heteroresistance?\" | Read-based deep variant calling supplements assembly-based AMR for clinically critical drugs; report MAF |\n| \"Why not just trust ResFinder phenotype prediction?\" | EUCAST\u002FCLSI breakpoint year must be documented; rule-based phenotype prediction inherits its curation as a hidden dependency. Pair with explicit gene + class reporting |\n| \"Why long-read assembly for AMR?\" | Short-read drafts fragment plasmid contigs and lose MGE \u002F promoter context (e.g., IS*Ecp1* upstream of ampC; Tn4401 variants); long-read or hybrid is mandatory for any mobility \u002F regulatory claim |\n| \"Why hAMRonization rather than tool-native outputs?\" | Cross-tool comparison requires schema unification; PHA4GE is the public-health consensus |\n| \"Was the intrinsic vs acquired distinction considered?\" | Yes -- `--organism` activates suppression of clinically inert intrinsic genes; reported separately |\n\n## References\n\n- Feldgarden M, Brover V, Haft DH et al (2021) AMRFinderPlus and the Reference Gene Catalog facilitate examination of the genomic links among antimicrobial resistance, stress response, and virulence. *Sci Rep* 11:12728. doi:10.1038\u002Fs41598-021-91456-0\n- Bortolaia V, Kaas RS, Ruppe E et al (2020) ResFinder 4.0 for predictions of phenotypes from genotypes. *J Antimicrob Chemother* 75(12):3491-3500. doi:10.1093\u002Fjac\u002Fdkaa345\n- Alcock BP, Huynh W, Chalil R et al (2023) CARD 2023: expanded curation, support for machine learning, and resistome prediction at the Comprehensive Antibiotic Resistance Database. *Nucleic Acids Res* 51(D1):D690-D699. doi:10.1093\u002Fnar\u002Fgkac920\n- Phelan JE, O'Sullivan DM, Machado D et al (2019) Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs. *Genome Med* 11:41. doi:10.1186\u002Fs13073-019-0650-x\n- Hunt M, Bradley P, Lapierre SG et al (2019) Antibiotic resistance prediction for Mycobacterium tuberculosis from genome sequence data with Mykrobe. *Wellcome Open Res* 4:191. doi:10.12688\u002Fwellcomeopenres.15603.1\n- Walker TM et al (CRyPTIC \u002F WHO) (2022) The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis. *Lancet Microbe* 3(4):e265-e273. doi:10.1016\u002FS2666-5247(21)00301-3\n- Allix-Béguec C et al (CRyPTIC) (2018) Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing. *N Engl J Med* 379(15):1403-1415. doi:10.1056\u002FNEJMoa1800474\n- Robertson J, Nash JHE (2018) MOB-suite: software tools for clustering, reconstruction and typing of plasmids from draft assemblies. *Microb Genom* 4(8):e000206. doi:10.1099\u002Fmgen.0.000206\n- Carattoli A, Zankari E, García-Fernández A et al (2014) In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob Agents Chemother* 58(7):3895-3903. doi:10.1128\u002FAAC.02412-14\n- Johansson MHK, Bortolaia V, Tansirichaiya S et al (2021) Detection of mobile genetic elements associated with antibiotic resistance in Salmonella enterica using a newly developed web tool: MobileElementFinder. *J Antimicrob Chemother* 76(1):101-109. doi:10.1093\u002Fjac\u002Fdkaa390\n- Sherry NL, Horan KA, Ballard SA et al (2023) An ISO-certified genomics workflow for identification and surveillance of antimicrobial resistance. *Nat Commun* 14:60. doi:10.1038\u002Fs41467-022-35713-4\n- Andersson DI, Nicoloff H, Hjort K (2019) Mechanisms and clinical relevance of bacterial heteroresistance. *Nat Rev Microbiol* 17(8):479-496. doi:10.1038\u002Fs41579-019-0218-1\n- Liu YY, Wang Y, Walsh TR et al (2016) Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China. *Lancet Infect Dis* 16(2):161-168. doi:10.1016\u002FS1473-3099(15)00424-7\n\n## Related Skills\n\n- pathogen-typing - Strain context for AMR (Kleborate, MLST, cgMLST) feeds clonal interpretation of resistance dissemination\n- transmission-inference - Outbreak transmission inference for resistant clones uses AMR + cgMLST jointly\n- variant-surveillance - Lineage-level AMR-prevalence tracking for SARS-CoV-2-style surveillance (drug-resistance mutations in antiviral context)\n- metagenomics\u002Famr-detection - Community AMR \u002F ARG quantification (NOT isolate-focused)\n- variant-calling\u002Fvariant-calling - Per-isolate SNP calling that feeds point-mutation panels\n- variant-calling\u002Ffiltering-best-practices - MAF threshold discipline for heteroresistance detection\n- long-read-sequencing\u002Flong-read-alignment - Plasmid \u002F promoter-context resolution for MGE-aware AMR\n- comparative-genomics\u002Fwhole-genome-alignment - Reference-based coordinate handling for point mutations\n- clinical-databases\u002Fpharmacogenomics - Adjacent (host-side) pharmacogenetics, distinct from pathogen AMR\n- workflows\u002Fsomatic-variant-pipeline - End-to-end orchestration patterns (analogous to outbreak-pipeline workflows)\n","## Version Compatibility\n\nReference examples tested with: ncbi-amrfinderplus 4.0+, resfinder 4.5+, rgi 6.0+ (CARD 3.3+), abritamr 1.0.14+, staramr 0.10+, hamronization 1.1+, tb-profiler 6.2+, mykrobe 0.13+, mob_suite 3.1+, plasmidfinder 2.1+, MobileElementFinder 1.0+, pandas 2.2+, BioPython 1.84+.\n\nBefore using code patterns, verify installed versions match. If versions differ:\n- Python: `pip show \u003Cpackage>` then `help(module.function)` to check signatures\n- CLI: `\u003Ctool> --version` then `\u003Ctool> --help` to confirm flags\n- AMRFinderPlus: `amrfinder --list_organisms` for the current `--organism` catalogue\n- WHO Mtb catalogue: `tb-profiler list_db` and verify the bundled WHO edition\n- AMR database freshness: `amrfinder -u` (NCBI ReferenceGeneCatalog) and `tb-profiler update_tbdb`\n\nIf a flag or column name does not match (`--species` vs `--organism`, `barcode_build` vs `barcode-build`), introspect the installed package rather than retrying. AMRFinderPlus, RGI, and ResFinder all renamed columns between major releases.\n\n# AMR Surveillance\n\n**\"What antibiotic-resistance determinants are in this assembly, and what susceptibility do they imply?\"** -> Combine acquired-gene detection, chromosomal point-mutation calling, mobile-element context, and curated phenotype mapping into a single per-isolate report fit for surveillance or clinical handover. Tool choice is determined by species (Mtb needs TB-Profiler, not AMRFinderPlus), reporting standard (WHO GLASS vs CARD vs in-house), and whether mobility matters (carbapenemase outbreak: yes; routine ESBL screen: less so).\n\n- CLI: `amrfinder -n assembly.fa --organism Klebsiella_pneumoniae --plus` -- acquired + intrinsic-aware point mutations\n- CLI: `tb-profiler profile -1 r1.fq.gz -2 r2.fq.gz -p sample` -- TB drug-resistance against WHO 2nd-edition catalogue\n- CLI: `hamronize amrfinderplus --analysis_software_version 4.0.3 --reference_database_version 2025-02-01.1 in.tsv > out.tsv` -- normalise output across tools\n- Python: `pandas` to join AMRFinderPlus + RGI + ResFinder + MOB-suite per-isolate for a single decision table\n\n## The Single Most Important Modern Insight -- Acquired AMR detection is not species-agnostic\n\nA pan-species AMRFinderPlus run misses chromosomal point-mutation resistance because the point-mutation panels are species-specific and activated only when `--organism` is set. Running `amrfinder -n mtb.fa` without `--organism` returns \"no AMR detected\" on an XDR-TB genome because AMRFinderPlus has no Mtb organism mode -- the user must switch tools (TB-Profiler or Mykrobe + WHO 2nd-edition catalogue). Similarly, *Salmonella* gyrA T83I, *Klebsiella* mgrB inactivation, and *E. coli* QRDR mutations are silent without `--organism Salmonella` \u002F `Klebsiella_pneumoniae` \u002F `Escherichia`. For any cross-tool surveillance pipeline, AMRFinderPlus with `--organism` MUST be paired with a species-specific second tool (TB-Profiler for Mtb; ResFinder 4.0 with `-s 'species'` for PointFinder coverage; hAMRonization to merge). Andersson et al. *Nat Rev Microbiol* 17:479 (2019) further notes that heteroresistance at 0.1-1% allele frequency is widespread and invisible to default variant callers, compounding the failure mode for any single-tool workflow.\n\n## Algorithmic Taxonomy\n\n| Tool | Mechanism | Inputs | Output | Strength | Fails when |\n|------|-----------|--------|--------|----------|------------|\n| AMRFinderPlus (Feldgarden 2021 *Sci Rep* 11:12728) | Curated HMM + BLAST against NCBI ReferenceGeneCatalog; per-gene cutoffs | assembly or protein | gene + class + element-type | Gene-family-aware (catches divergent variants); built-in species point-mutation panels | No Mtb mode; reports intrinsic genes unless `--organism` set |\n| ResFinder 4.0 (Bortolaia 2020 *J Antimicrob Chemother* 75:3491) | BLAST against ResFinder DB (acquired) + PointFinder DB (chromosomal mutations) per species | assembly or reads | gene + predicted phenotype (S\u002FI\u002FR) | Phenotype prediction tied to CLSI\u002FEUCAST | Requires explicit `-s 'species'` for PointFinder; default 90\u002F60 cutoffs hide divergent variants |\n| CARD-RGI (Alcock 2023 *NAR* 51:D690) | BLAST + HMM against CARD; tiers Perfect \u002F Strict \u002F Loose | assembly or protein | ARO ontology term, model-type (homolog \u002F variant \u002F overexpression \u002F knockout \u002F rRNA) | Mechanism-resolved (operons modelled); ARO ontology is curated | Loose tier produces many false positives; default Strict+Perfect misses real variants in non-model organisms |\n| abritAMR (Sherry 2023 *Nat Commun* 14:60) | AMRFinderPlus wrapper + drug-class classifier; ISO-certified for clinical use | assembly | gene + drug class | First ISO-certified AMR pipeline; accredited reporting categories | Limited to AMRFinderPlus's underlying gene panel |\n| staramr | ResFinder + PointFinder + PlasmidFinder + MLST in one pipeline | assembly | combined report | One-shot Salmonella \u002F E. coli \u002F Campylobacter surveillance | Default organism handling can hide point mutations; verify each component version |\n| TB-Profiler (Phelan 2019 *Genome Med* 11:41) | Maps reads or assembly against H37Rv + WHO catalogue + Coll\u002FNapier lineage barcode | reads or assembly | per-drug R\u002FR-interim\u002FUncertain\u002FS + lineage | WHO 2nd-edition catalogue integration; lineage call; heteroresistance from allele frequency | Hardcoded to MTBC; older bundled DB may predate current WHO edition |\n| Mykrobe (Hunt 2019 *Wellcome Open Res* 4:191) | k-mer presence\u002Fabsence against curated panel | reads | species + AMR per drug | k-mer-fast; cross-checks TB-Profiler; supports Mtb, S. aureus, Salmonella, gonorrhoea | Panel may lag WHO catalogue; check `--panel` |\n| hAMRonization (PHA4GE) | Format converter to PHA4GE schema | per-tool TSV | unified TSV\u002FJSON | Cross-tool comparison; surveillance harmonisation | Mandatory metadata fields differ per tool subparser |\n\n## Decision Tree by Scenario\n\n| Scenario | Recommended | Why wrong choices fail |\n|----------|-------------|------------------------|\n| Routine screen of an *E. coli* \u002F *Klebsiella* \u002F *Salmonella* assembly for acquired AMR + point mutations | AMRFinderPlus with `--organism Escherichia` \u002F `Klebsiella_pneumoniae` \u002F `Salmonella` + `--plus` | Without `--organism`: no PointFinder panel, fluoroquinolone QRDR mutations missed; intrinsic-gene noise in Klebsiella |\n| *M. tuberculosis* drug-resistance prediction | TB-Profiler interpreted via WHO 2nd-edition catalogue, Mykrobe as cross-check on R\u002FXDR isolates | AMRFinderPlus has no Mtb organism mode; ResFinder PointFinder lacks the full WHO catalogue; tool defaults silently call Group 3 mutations as \"susceptible\" |\n| Predict S\u002FI\u002FR phenotype, not gene presence | ResFinder 4.0 OR abritAMR; document EUCAST or CLSI breakpoint year | AMRFinderPlus reports presence only; mapping presence -> phenotype needs curated rules |\n| Carbapenemase outbreak: is the gene mobile? | AMRFinderPlus -> MOB-suite (`mob_recon` + `mob_typer`) -> cross-reference; long-read or hybrid assembly recommended | PlasmidFinder alone gives replicon type but not gene-plasmid linkage; short-read draft assemblies fragment plasmid contigs and lose context |\n| Cross-laboratory surveillance reporting | Pass per-tool output through hAMRonization to PHA4GE schema; populate `analysis_software_version` and `reference_database_version` | Raw cross-tool comparison is meaningless (CARD ARO vs ResFinder name vs NCBI ReferenceGeneCatalog) |\n| Novel-variant surveillance (emergence) | AMRFinderPlus (HMM, gene-family-aware) OR CARD-RGI with Loose-tier manual review | abricate's 80\u002F80 defaults reject divergent family members; pure-BLAST defaults silently miss novel mcr \u002F OXA sub-variants |\n| Quantitative AMR from metagenomic reads | AMRPlusPlus \u002F DeepARG \u002F ARGs-OAP normalised to 16S; report \"ARG abundance\" NOT \"resistance\" | Assembly-based tools fail on short reads; reporting environmental ARG counts as \"resistance\" inherits the environmental-resistome critique that homolog presence is not phenotypic resistance |\n| Colistin resistance in *Klebsiella* \u002F *Enterobacter* \u002F *Salmonella* | mcr-1 to mcr-10 acquired (AMRFinderPlus; mcr-1 originally Liu 2016 *Lancet Infect Dis* 16:161) + mgrB \u002F pmrAB \u002F phoPQ point mutations (`--organism Klebsiella_pneumoniae`) + phenotypic confirmation for mcr-9\u002F10 | mcr-9 \u002F mcr-10 frequently report without elevated MIC; treating mcr presence as \"colistin-R\" triggers infection control unnecessarily |\n| WHO GLASS submission | hAMRonization -> drug-class mapping -> EUCAST\u002FCLSI breakpoint interpretation; record breakpoint year | Gene-level reporting without class mapping cannot populate GLASS categories |\n\nMethodology evolves rapidly; before a high-stakes outbreak report, web-search \"AMRFinderPlus organism modes 2026\" and confirm the WHO Mtb catalogue edition currently bundled in TB-Profiler.\n\n## AMRFinderPlus With Species Mode\n\n**Goal:** Produce a per-isolate AMR report including acquired genes, species-specific chromosomal point mutations, stress\u002Fvirulence elements, and per-hit method and coverage metadata for downstream harmonisation.\n\n**Approach:** Run `amrfinder` with `-n` for nucleotide assembly, `--organism` to activate the species-specific point-mutation panel, `--plus` to include stress \u002F virulence \u002F heat \u002F metal, and `--report_all` when truncated-gene visibility matters. Pin the database via `amrfinder -u` -> verify `--db` matches a recorded date.\n\n```bash\nDB=$(amrfinder -V | grep -i database | awk '{print $NF}')\n\namrfinder \\\n    -n assembly.fa \\\n    --organism Klebsiella_pneumoniae \\\n    --plus \\\n    --threads 8 \\\n    -o sample.amrfinder.tsv\n\necho \"DB version: ${DB}\" >> sample.amrfinder.tsv\n```\n\nColumn semantics worth inspecting: `Element type` (AMR \u002F POINT \u002F VIRULENCE \u002F STRESS \u002F etc.), `Method` (EXACTX \u002F PARTIAL_CONTIG_END \u002F HMM \u002F etc. -- partial-contig hits flag assembly fragmentation), `% Coverage of reference sequence`, `% Identity to reference sequence`, `Class` \u002F `Subclass` (drug-class summary). `Method = PARTIAL_CONTIG_END` is the smoking gun for plasmid-context fragmentation -- consider long-read confirmation.\n\n## TB-Specific Workflow\n\n**Goal:** Generate a WHO-catalogue-aligned drug-resistance report for *M. tuberculosis* covering all 13 first-line + second-line + new\u002Frepurposed drugs, with lineage assignment via the Coll\u002FNapier MTBC barcode (90-SNP version) and explicit handling of Group 3 (Uncertain) mutations.\n\n**Approach:** TB-Profiler primary (it bundles the WHO catalogue and reports the Walker 2022 \u002F 2023 association grouping); Mykrobe as an orthogonal cross-check on any R \u002F XDR call that will drive treatment. NEVER collapse Group 3 mutations to \"susceptible\" -- the WHO catalogue's tiered scoring is load-bearing for clinical handover.\n\n```bash\ntb-profiler update_tbdb\n\ntb-profiler profile \\\n    -1 reads_R1.fq.gz \\\n    -2 reads_R2.fq.gz \\\n    -p sample \\\n    --txt --csv --pdf \\\n    --dir tbprofiler_out\n\nmykrobe predict \\\n    --sample sample \\\n    --species tb \\\n    --output sample.mykrobe.json \\\n    --format json \\\n    reads_R1.fq.gz reads_R2.fq.gz\n```\n\nAllix-Béguec et al. (CRyPTIC) *NEJM* 379:1403 (2018) established >99% negative predictive value for first-line drugs and is the basis for WGS-only DST policies; the same study showed sensitivity remains lower for bedaquiline, delamanid, linezolid, and clofazimine, so phenotypic DST is still required for second-line and new\u002Frepurposed agents in MDR\u002FXDR-TB workups. The WHO 2023 catalogue (Walker et al. *Lancet Microbe* 3:e265, 2022 for the 2021 edition methodology; 2023 second edition data) grades each mutation **Group 1** \u002F **Group 2** (Associated -- interim) \u002F **Group 3** (Uncertain) \u002F **Group 4** (Not Associated -- interim) \u002F **Group 5** (Not Associated). Reporting Group 3 as \"S\" actively misleads clinicians.\n\n## hAMRonization for Cross-Tool Reporting\n\n**Goal:** Convert per-tool AMR output (AMRFinderPlus, ResFinder, RGI, abricate, staramr, ARIBA, TB-Profiler, Mykrobe) to the PHA4GE schema so a multi-laboratory or multi-tool surveillance dataset is comparable.\n\n**Approach:** Invoke `hamronize \u003Ctool>` per input with mandatory provenance metadata (`--analysis_software_version`, `--reference_database_version`, `--input_file_name`), then `hamronize summarize` to merge.\n\n```bash\nhamronize amrfinderplus \\\n    --analysis_software_version 4.0.3 \\\n    --reference_database_version 2025-02-01.1 \\\n    --input_file_name sample.amrfinder.tsv \\\n    sample.amrfinder.tsv > sample.hamr.tsv\n\nhamronize resfinder \\\n    --analysis_software_version 4.5.0 \\\n    --reference_database_version 2024-12-15 \\\n    --input_file_name sample.resfinder.json \\\n    sample.resfinder.json > sample.resfinder.hamr.tsv\n\nhamronize summarize -t tsv -o cohort.hamr.tsv per_sample_hamr\u002F*.tsv\n```\n\nDefault reporting ontology for public-health output is NCBI ReferenceGeneCatalog. Two consequences: (1) CARD ARO terms need translation; (2) any custom gene additions need a corresponding NCBI accession before they appear in the harmonised stream.\n\n## Mobile-Genetic-Element Context\n\n**Goal:** Determine whether a clinically actionable AMR gene (carbapenemase, mcr, ESBL) sits on a chromosome, a plasmid (and which incompatibility group \u002F cluster), an integrative-conjugative element, or a transposon -- because \"gene present\" tells the infection-control team nothing about transmissibility.\n\n**Approach:** Reconstruct plasmids from the assembly with MOB-suite `mob_recon`; type each plasmid with `mob_typer`; cross-reference AMR-gene coordinates against the plasmid contig list; annotate IS elements \u002F integrons with MobileElementFinder. For surveillance-grade plasmid resolution, prefer long-read (R10.4.1 Q20+) or hybrid assemblies -- short-read draft assemblies routinely fragment plasmid contigs.\n\n```bash\nmob_recon \\\n    --infile assembly.fa \\\n    --outdir mob_out\u002F \\\n    --num_threads 4\n\nmob_typer \\\n    --infile mob_out\u002Fplasmid_AA001.fasta \\\n    --out_file mob_out\u002Fplasmid_AA001.typed.tsv\n\nmefinder find \\\n    --contig assembly.fa \\\n    --out mef_out\u002Fsample \\\n    --threads 4\n```\n\nDocument MOB-suite version explicitly: v2 and v3 cluster codes are non-interoperable, and v3.1+ adds MGE reporting. Across longitudinal surveillance crossing the v2 -> v3 boundary, the same plasmid receives different cluster IDs and appears spuriously \"novel\".\n\n## Per-Method Failure Modes\n\n### AMRFinderPlus run pan-species on a *Mycobacterium tuberculosis* assembly\n\n**Trigger:** `amrfinder -n mtb.fa` without `--organism`; AMRFinderPlus has no Mtb organism mode in any v4.x release.\n\n**Mechanism:** The species-specific point-mutation panels are activated only when a recognised `--organism` is passed. Mtb resistance is overwhelmingly chromosomal point mutation (rpoB \u002F katG \u002F inhA \u002F pncA \u002F embB \u002F gyrA \u002F rrs). With no panel active, none of these are called.\n\n**Symptom:** Empty AMR table on a phenotypically MDR\u002FXDR isolate; lineage barcode not reported (AMRFinderPlus does not call MTBC lineage).\n\n**Fix:** Switch tools. Use TB-Profiler (preferred -- bundles WHO catalogue + Coll\u002FNapier barcode) or Mykrobe; the AMRFinderPlus catalogue does not cover MTBC.\n\n### OXA-48-like family collapsed to a single bucket\n\n**Trigger:** Default per-isolate summarisers report the gene family (`bla_OXA-48-like`) rather than the allele (`bla_OXA-244`).\n\n**Mechanism:** OXA-48 (potent carbapenemase), OXA-181 (Thr213Ala -- similar activity, different plasmid), OXA-232 (Arg214Ser -- reduced carbapenemase activity), and OXA-244 (Arg214Gly -- weakest, often phenotypically susceptible to ertapenem) share >95% identity. Pipelines that report family-level summary erase the clinically actionable variant identity.\n\n**Symptom:** Surveillance report says \"OXA-48-like detected\", phenotype is borderline ertapenem-susceptible \u002F meropenem-susceptible, clinical team is confused about whether ceftazidime-avibactam is needed.\n\n**Fix:** Report the allele explicitly; never collapse to family. AMRFinderPlus reports the allele in `Gene symbol` -- preserve it through hAMRonization rather than summarising.\n\n### IS-element-mediated derepression invisible to gene-presence pipelines\n\n**Trigger:** Phenotypic high-level AmpC hyperproduction in *Enterobacter cloacae* complex \u002F *Citrobacter freundii*; or KPC over-expression on Tn4401b (100-bp promoter deletion).\n\n**Mechanism:** Resistance is mediated by IS*Ecp1* \u002F IS*26* \u002F IS*10* insertion upstream of the ampC promoter producing a strong hybrid promoter, or by Tn4401 variant. Gene presence is unchanged. Short-read assemblies fragment IS elements and collapse repeats; promoter context is lost. AMRFinderPlus \u002F RGI \u002F ResFinder report the gene; the regulatory configuration is not annotated.\n\n**Symptom:** AMR pipeline output identical for wild-type ampC carrier and the hyperproducer; clinical phenotype is divergent.\n\n**Fix:** Long-read (Nanopore R10.4.1 Q20+ or PacBio HiFi) or hybrid assembly with explicit promoter-context inspection. For Tn4401 variant typing, manual blast of the transposon region. Tools that automate this are emerging but not yet a default in surveillance pipelines.\n\n### Heteroresistance below default variant-caller thresholds\n\n**Trigger:** Routine Illumina WGS-AMR pipeline on a clinical isolate; resistance variant appears at 1-5% allele frequency.\n\n**Mechanism:** Heteroresistance -- clonal subpopulations carrying resistance at 0.1-1% (Andersson, Nicoloff, Hjort *Nat Rev Microbiol* 17:479, 2019) -- is widespread and clinically meaningful (treatment failure under antibiotic pressure). Default variant callers (`bcftools`, `lofreq` default `-q 20`, GATK HaplotypeCaller) require minor-allele frequency of typically 10-20% to call. Assembly-based pipelines (AMRFinderPlus on assembly) collapse minor variants entirely.\n\n**Symptom:** Surveillance pipeline calls \"S\" but clinical failure under therapy; subsequent sampling reveals high-level resistance.\n\n**Fix:** For clinically critical drugs, supplement assembly-based AMR with deep-read variant calling at lower MAF thresholds (`lofreq` with `-q 13 -a 0.01`), or use targeted deep-amplicon sequencing. TB-Profiler reports allele frequency for resistance calls -- inspect for heteroresistance routinely.\n\n### WHO Mtb Group 3 mutations silently called \"susceptible\"\n\n**Trigger:** TB-Profiler \u002F Mykrobe run on an Mtb isolate carrying a mutation graded Group 3 (Uncertain) in the WHO catalogue.\n\n**Mechanism:** Tools translate Group 3 calls to \"no resistance prediction\" in their summary; downstream summarisers and clinical handover forms collapse \"no prediction\" to \"S\". The Walker 2022 *Lancet Microbe* catalogue methodology explicitly separates Group 3 (Uncertain) from Group 4\u002F5 (Not Associated) for exactly this reason.\n\n**Symptom:** Patient treated as drug-susceptible; clinical failure; retrospective inspection finds Group 3 mutation that should have triggered phenotypic DST.\n\n**Fix:** Read TB-Profiler JSON output, NOT the simplified TSV. Report Group 3 mutations explicitly with \"uncertain significance -- phenotypic DST recommended\". This is widely under-communicated in surveillance pipelines.\n\n### fosA \u002F efflux-regulator hits overcalled as resistance\n\n**Trigger:** Chromosomal fosA in *Klebsiella pneumoniae* \u002F *Enterobacter* \u002F *Serratia* reported as \"fosfomycin resistant\" by ResFinder \u002F AMRFinderPlus.\n\n**Mechanism:** Chromosomal fosA confers low-level fosfomycin resistance below the EUCAST clinical breakpoint (32 mg\u002FL for urinary isolates). Treating chromosomal-fosA *E. coli* as fosfomycin-resistant withholds an oral option for uncomplicated UTI unnecessarily.\n\n**Symptom:** All *K. pneumoniae* isolates flagged \"fosfomycin-R\" regardless of plasmid context or phenotype.\n\n**Fix:** AMRFinderPlus with `--organism Klebsiella_pneumoniae` suppresses the intrinsic fosA report; verify the suppression worked. Cross-reference fosA hits with MOB-suite to determine plasmid context; only plasmid-borne or upregulated fosA should be reported as resistance.\n\n## Reconciliation: When AMR Tools Disagree\n\n| Pattern | Likely cause | Action |\n|---------|--------------|--------|\n| AMRFinderPlus calls `bla_NDM-5`; ResFinder calls `bla_NDM-1` | Allele assignment differs by reference database (NCBI ReferenceGeneCatalog vs ResFinder DB); both are within the NDM family | Report the family + flag the allele discordance; for clinical handover prefer NCBI nomenclature, for legacy comparability prefer ResFinder |\n| RGI calls `mecA` \"Strict\"; AMRFinderPlus calls \"EXACTX\" | Tier semantics differ; both real hits | Concordant resistance call -- harmonise via hAMRonization, use NCBI ReferenceGeneCatalog nomenclature |\n| ResFinder reports a gene at 88% identity; AMRFinderPlus omits | ResFinder default 90\u002F60; AMRFinderPlus HMM cutoff stricter for that family | Manual review; for novel-variant surveillance, AMRFinderPlus + Loose-tier RGI catches more |\n| TB-Profiler and Mykrobe disagree on isoniazid | Different curated panels; one may predate WHO 2nd edition | Defer to TB-Profiler interpreted against WHO catalogue; manual blast of katG \u002F inhA \u002F fabG1 |\n| mcr-9 detected; phenotypic colistin MIC susceptible | Expected -- mcr-9 frequently silent without IqrR \u002F induction | Report mcr-9 detection + susceptibility; do NOT trigger infection-control as if MCR-1 |\n| AMRFinderPlus `Method=PARTIAL_CONTIG_END` for a carbapenemase | Assembly fragmentation at the plasmid edge | Re-assemble with long reads or hybrid before reporting; the gene may be present in full |\n| RGI calls a long list of \"Loose\" hits | Non-model organism or distant lineage | Manual curation of Loose hits -- discard generic homologs, retain those near canonical AMR-active residues |\n\n## Quantitative Thresholds\n\n| Quantity | Threshold | Source \u002F rationale |\n|----------|-----------|--------------------|\n| AMRFinderPlus default %identity | per-gene curated (typically 90% global) | Feldgarden 2021 *Sci Rep* 11:12728; HMM cutoff is gene-family-aware |\n| AMRFinderPlus default %coverage | 50% (alignment coverage) | NCBI Reference; `--report_all` exposes partial hits |\n| ResFinder default %id \u002F %coverage | 90% \u002F 60% | CGE convention; tighter than abricate |\n| abricate default %id \u002F %coverage | 80% \u002F 80% | Too permissive for novel-variant surveillance |\n| WHO Mtb Group 1 (Associated with R) | High-confidence resistance call | Walker 2022 *Lancet Microbe* 3:e265 |\n| WHO Mtb Group 3 (Uncertain) | NOT \"susceptible\" -- phenotypic DST recommended | Walker 2022 *Lancet Microbe* 3:e265; 2023 2nd edition data |\n| Heteroresistance MAF | 0.1-1% (deep amplicon detection) | Andersson 2019 *Nat Rev Microbiol* 17:479 |\n| EUCAST fosfomycin urinary breakpoint | 32 mg\u002FL | EUCAST clinical breakpoint tables (year-specific) |\n| Variant MAF for routine WGS-AMR calling | 10% (`lofreq` default), 20% (GATK default) | Tool defaults; document per-pipeline |\n\n## Common Errors\n\n| Error \u002F symptom | Cause | Solution |\n|-----------------|-------|----------|\n| AMRFinderPlus empty on TB assembly | No Mtb `--organism` mode | Switch to TB-Profiler \u002F Mykrobe |\n| AMRFinderPlus calls intrinsic fosA on Klebsiella | `--organism` not set; intrinsic suppression off | Always pass `--organism` for the species |\n| `--species` flag rejected | AMRFinderPlus uses `--organism`, not `--species` | Use `--organism Klebsiella_pneumoniae` |\n| Different gene names for same determinant across tools | CARD ARO vs ResFinder vs NCBI ReferenceGeneCatalog | Pass through `hamronize` |\n| `Method=PARTIAL_CONTIG_END` on a clinically critical gene | Assembly fragmentation | Re-assemble with long reads \u002F hybrid |\n| `hamronize` rejects input as missing metadata | `--analysis_software_version` not supplied | Populate all mandatory PHA4GE fields per tool subparser |\n| MOB-suite cluster codes don't match published outbreak paper | v2 vs v3 incompatibility | Re-run with matched MOB-suite version; document |\n| Point-mutation panel coverage list flips between AMRFinderPlus minor releases | DB schema change | `amrfinder --list_organisms` and record the version |\n| TB-Profiler bundled DB predates WHO 2nd edition | DB not updated | `tb-profiler update_tbdb` and verify catalogue edition |\n\n## Anticipated Reviewer Pushback\n\n| Pushback | Response |\n|----------|----------|\n| \"Why AMRFinderPlus, not RGI?\" | AMRFinderPlus uses gene-family HMMs and NCBI-curated cutoffs that catch divergent novel variants without producing the Loose-tier noise of RGI; both are valid and `hamronize` lets the reviewer compare |\n| \"How were Group 3 WHO Mtb mutations handled?\" | Reported as \"Uncertain significance -- phenotypic DST recommended\"; not collapsed to S |\n| \"What about heteroresistance?\" | Read-based deep variant calling supplements assembly-based AMR for clinically critical drugs; report MAF |\n| \"Why not just trust ResFinder phenotype prediction?\" | EUCAST\u002FCLSI breakpoint year must be documented; rule-based phenotype prediction inherits its curation as a hidden dependency. Pair with explicit gene + class reporting |\n| \"Why long-read assembly for AMR?\" | Short-read drafts fragment plasmid contigs and lose MGE \u002F promoter context (e.g., IS*Ecp1* upstream of ampC; Tn4401 variants); long-read or hybrid is mandatory for any mobility \u002F regulatory claim |\n| \"Why hAMRonization rather than tool-native outputs?\" | Cross-tool comparison requires schema unification; PHA4GE is the public-health consensus |\n| \"Was the intrinsic vs acquired distinction considered?\" | Yes -- `--organism` activates suppression of clinically inert intrinsic genes; reported separately |\n\n## References\n\n- Feldgarden M, Brover V, Haft DH et al (2021) AMRFinderPlus and the Reference Gene Catalog facilitate examination of the genomic links among antimicrobial resistance, stress response, and virulence. *Sci Rep* 11:12728. doi:10.1038\u002Fs41598-021-91456-0\n- Bortolaia V, Kaas RS, Ruppe E et al (2020) ResFinder 4.0 for predictions of phenotypes from genotypes. *J Antimicrob Chemother* 75(12):3491-3500. doi:10.1093\u002Fjac\u002Fdkaa345\n- Alcock BP, Huynh W, Chalil R et al (2023) CARD 2023: expanded curation, support for machine learning, and resistome prediction at the Comprehensive Antibiotic Resistance Database. *Nucleic Acids Res* 51(D1):D690-D699. doi:10.1093\u002Fnar\u002Fgkac920\n- Phelan JE, O'Sullivan DM, Machado D et al (2019) Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs. *Genome Med* 11:41. doi:10.1186\u002Fs13073-019-0650-x\n- Hunt M, Bradley P, Lapierre SG et al (2019) Antibiotic resistance prediction for Mycobacterium tuberculosis from genome sequence data with Mykrobe. *Wellcome Open Res* 4:191. doi:10.12688\u002Fwellcomeopenres.15603.1\n- Walker TM et al (CRyPTIC \u002F WHO) (2022) The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis. *Lancet Microbe* 3(4):e265-e273. doi:10.1016\u002FS2666-5247(21)00301-3\n- Allix-Béguec C et al (CRyPTIC) (2018) Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing. *N Engl J Med* 379(15):1403-1415. doi:10.1056\u002FNEJMoa1800474\n- Robertson J, Nash JHE (2018) MOB-suite: software tools for clustering, reconstruction and typing of plasmids from draft assemblies. *Microb Genom* 4(8):e000206. doi:10.1099\u002Fmgen.0.000206\n- Carattoli A, Zankari E, García-Fernández A et al (2014) In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob Agents Chemother* 58(7):3895-3903. doi:10.1128\u002FAAC.02412-14\n- Johansson MHK, Bortolaia V, Tansirichaiya S et al (2021) Detection of mobile genetic elements associated with antibiotic resistance in Salmonella enterica using a newly developed web tool: MobileElementFinder. *J Antimicrob Chemother* 76(1):101-109. doi:10.1093\u002Fjac\u002Fdkaa390\n- Sherry NL, Horan KA, Ballard SA et al (2023) An ISO-certified genomics workflow for identification and surveillance of antimicrobial resistance. *Nat Commun* 14:60. doi:10.1038\u002Fs41467-022-35713-4\n- Andersson DI, Nicoloff H, Hjort K (2019) Mechanisms and clinical relevance of bacterial heteroresistance. *Nat Rev Microbiol* 17(8):479-496. doi:10.1038\u002Fs41579-019-0218-1\n- Liu YY, Wang Y, Walsh TR et al (2016) Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China. *Lancet Infect Dis* 16(2):161-168. doi:10.1016\u002FS1473-3099(15)00424-7\n\n## Related Skills\n\n- pathogen-typing - Strain context for AMR (Kleborate, MLST, cgMLST) feeds clonal interpretation of resistance dissemination\n- transmission-inference - Outbreak transmission inference for resistant clones uses AMR + cgMLST jointly\n- variant-surveillance - Lineage-level AMR-prevalence tracking for SARS-CoV-2-style surveillance (drug-resistance mutations in antiviral context)\n- metagenomics\u002Famr-detection - Community AMR \u002F ARG quantification (NOT isolate-focused)\n- variant-calling\u002Fvariant-calling - Per-isolate SNP calling that feeds point-mutation panels\n- variant-calling\u002Ffiltering-best-practices - MAF threshold discipline for heteroresistance detection\n- long-read-sequencing\u002Flong-read-alignment - Plasmid \u002F promoter-context resolution for MGE-aware AMR\n- comparative-genomics\u002Fwhole-genome-alignment - Reference-based coordinate handling for point mutations\n- clinical-databases\u002Fpharmacogenomics - Adjacent (host-side) pharmacogenetics, distinct from pathogen AMR\n- workflows\u002Fsomatic-variant-pipeline - End-to-end orchestration patterns (analogous to outbreak-pipeline workflows)\n",{"name":5,"source":24,"license":15,"tool_type":25,"description":7,"imported_at":26,"source_path":27,"primary_tool":28,"source_repository":29},"https:\u002F\u002Fgithub.com\u002FGPTomics\u002FbioSkills","mixed","2026-09-20","epidemiological-genomics\u002Famr-surveillance\u002FSKILL.md","AMRFinderPlus","GPTomics\u002FbioSkills","main","2d1750717747097b602acf30bd09a7cbd4b4c6ea","awesome_skills\u002Fbiology\u002Fbio-epidemiological-genomics-amr-surveillance","https:\u002F\u002Fgithub.com\u002FMr-Nobody-Anonymous\u002FAll-skills","https:\u002F\u002Fgithub.com\u002FMr-Nobody-Anonymous","2026-11-09 11:45:36",{"source":8,"skillName":5,"commands":37,"prompt":47,"zipAvailable":48},[38,41,44],{"tool":39,"command":40},"npx","npx skills add Mr-Nobody-Anonymous\u002FAll-skills --skill bio-epidemiological-genomics-amr-surveillance",{"tool":42,"command":43},"bunx","bunx skills add Mr-Nobody-Anonymous\u002FAll-skills --skill bio-epidemiological-genomics-amr-surveillance",{"tool":45,"command":46},"pnpm","pnpm dlx skills add Mr-Nobody-Anonymous\u002FAll-skills --skill bio-epidemiological-genomics-amr-surveillance","安装技能，技能地址：https:\u002F\u002Fgithub.com\u002FMr-Nobody-Anonymous\u002FAll-skills\u002Fblob\u002Fmain\u002Fawesome_skills\u002Fbiology\u002Fbio-epidemiological-genomics-amr-surveillance\u002FSKILL.md",true,[50,56],{"path":51,"resourceType":52,"resourceTypeDesc":53,"sizeBytes":54,"sourceHtmlUrl":55},"examples\u002Famr_surveillance.py","SCRIPT","脚本",7150,"https:\u002F\u002Fgithub.com\u002FMr-Nobody-Anonymous\u002FAll-skills\u002Fblob\u002Fmain\u002Fawesome_skills\u002Fbiology\u002Fbio-epidemiological-genomics-amr-surveillance\u002Fexamples\u002Famr_surveillance.py",{"path":57,"resourceType":58,"resourceTypeDesc":59,"sizeBytes":60,"sourceHtmlUrl":61},"usage-guide.md","REFERENCE","参考文档",10097,"https:\u002F\u002Fgithub.com\u002FMr-Nobody-Anonymous\u002FAll-skills\u002Fblob\u002Fmain\u002Fawesome_skills\u002Fbiology\u002Fbio-epidemiological-genomics-amr-surveillance\u002Fusage-guide.md",[63,71,78,85,92,99],{"skillNo":64,"name":65,"nameZh":6,"description":66,"descriptionZh":6,"repositoryFullName":8,"ownerLogin":9,"ownerAvatarUrl":10,"ownerAccountNo":11,"ownerDisplayName":12,"repositoryNo":13,"starsCount":14,"licenseSpdxId":15,"licenseFileUrl":6,"sourceHtmlUrl":67,"categories":68,"keywords":69,"publishedAt":70},"01M7EXRQF9GFM7D9BG6N5HAT34","oath","Auditing regulatory compliance (SOC2\u002FPCI-DSS\u002FHIPAA\u002FISO 27001): maps requirements, checks controls, designs audit trails, implements Policy as Code. Use when compliance auditing is needed.","https:\u002F\u002Fgithub.com\u002FMr-Nobody-Anonymous\u002FAll-skills\u002Fblob\u002Fmain\u002Fawesome_skills\u002Fdevsecops\u002Foath\u002FSKILL.md",[],[],"2026-11-15 14:25:24",{"skillNo":72,"name":73,"nameZh":6,"description":74,"descriptionZh":6,"repositoryFullName":8,"ownerLogin":9,"ownerAvatarUrl":10,"ownerAccountNo":11,"ownerDisplayName":12,"repositoryNo":13,"starsCount":14,"licenseSpdxId":15,"licenseFileUrl":6,"sourceHtmlUrl":75,"categories":76,"keywords":77,"publishedAt":19},"01M7EXRH7TYTNZJT0BQXEWAMW7","nexus","Orchestrating multi-specialist task chains and scope-adaptive product delivery: classifies intent, selects and executes the minimum viable chain, aggregates results, and verifies acceptance criteria. For multi-domain tasks, build-first delivery, and product lifecycle execution.","https:\u002F\u002Fgithub.com\u002FMr-Nobody-Anonymous\u002FAll-skills\u002Fblob\u002Fmain\u002Fawesome_skills\u002Fdevsecops\u002Fnexus\u002FSKILL.md",[],[],{"skillNo":79,"name":80,"nameZh":6,"description":81,"descriptionZh":6,"repositoryFullName":8,"ownerLogin":9,"ownerAvatarUrl":10,"ownerAccountNo":11,"ownerDisplayName":12,"repositoryNo":13,"starsCount":14,"licenseSpdxId":15,"licenseFileUrl":6,"sourceHtmlUrl":82,"categories":83,"keywords":84,"publishedAt":19},"01M7EXRCDPFWVEEEFR2ZQGJCYY","nest","Designing LLM-optimized folder structures: audits and restructures directories for context efficiency, progressive disclosure, and prompt cache performance. Not for general repo structure (Grove).","https:\u002F\u002Fgithub.com\u002FMr-Nobody-Anonymous\u002FAll-skills\u002Fblob\u002Fmain\u002Fawesome_skills\u002Fdevsecops\u002Fnest\u002FSKILL.md",[],[],{"skillNo":86,"name":87,"nameZh":6,"description":88,"descriptionZh":6,"repositoryFullName":8,"ownerLogin":9,"ownerAvatarUrl":10,"ownerAccountNo":11,"ownerDisplayName":12,"repositoryNo":13,"starsCount":14,"licenseSpdxId":15,"licenseFileUrl":6,"sourceHtmlUrl":89,"categories":90,"keywords":91,"publishedAt":19},"01M7EXR7JEER60TH0HD0AH4EE9","native","Implementing production iOS\u002FAndroid\u002FmacOS native features (SwiftUI, Compose) and iterating a screen against a reference design. Not for cross-platform RN\u002FFlutter (Port) or web (Artisan).","https:\u002F\u002Fgithub.com\u002FMr-Nobody-Anonymous\u002FAll-skills\u002Fblob\u002Fmain\u002Fawesome_skills\u002Fdevsecops\u002Fnative\u002FSKILL.md",[],[],{"skillNo":93,"name":94,"nameZh":6,"description":95,"descriptionZh":6,"repositoryFullName":8,"ownerLogin":9,"ownerAvatarUrl":10,"ownerAccountNo":11,"ownerDisplayName":12,"repositoryNo":13,"starsCount":14,"licenseSpdxId":15,"licenseFileUrl":6,"sourceHtmlUrl":96,"categories":97,"keywords":98,"publishedAt":19},"01M7EXR133J7DD5961R80QTRZY","muse","Defining and managing design tokens, applying token systems to existing codebases, building design system foundations. Use for spacing, color, typography, dark mode, cross-platform output.","https:\u002F\u002Fgithub.com\u002FMr-Nobody-Anonymous\u002FAll-skills\u002Fblob\u002Fmain\u002Fawesome_skills\u002Fdevsecops\u002Fmuse\u002FSKILL.md",[],[],{"skillNo":100,"name":101,"nameZh":6,"description":102,"descriptionZh":6,"repositoryFullName":8,"ownerLogin":9,"ownerAvatarUrl":10,"ownerAccountNo":11,"ownerDisplayName":12,"repositoryNo":13,"starsCount":14,"licenseSpdxId":15,"licenseFileUrl":6,"sourceHtmlUrl":103,"categories":104,"keywords":105,"publishedAt":19},"01M7EXQWWX7ECQN0J50B41YN5N","morph","Converting document formats (Markdown\u002FWord\u002FExcel\u002FPDF\u002FHTML) and generating reusable conversion scripts. Use for distributable specs, accessibility-compliant PDFs, or Pandoc\u002FLibreOffice pipelines.","https:\u002F\u002Fgithub.com\u002FMr-Nobody-Anonymous\u002FAll-skills\u002Fblob\u002Fmain\u002Fawesome_skills\u002Fdevsecops\u002Fmorph\u002FSKILL.md",[],[]]